Kimia Farma Eyeing 12.7 Percent Revenue Increase in 2021
Translator
Editor
29 April 2021 06:15 WIB
TEMPO.CO, Jakarta - Kimia Farma director of business director, Imam Fathorrahman, on Wednesday said the state-owned pharmaceutical firm is eyeing a Rp11.27 trillion in revenue for 2021, a number that is 12.7 percent higher than the firm’s sales in 2020.
Fathorrahman on April 28 said to Bisnis.com that the potential segments are “clinical diagnostic services mainly related to the vaccination program, business retail segments, and distribution.”
He also optimistically said the potential revenue may be generated from Kimia Farma’s manufacture holding.
According to the company’s financial report, the firm with issuer code KAEF had generated a total 2020 revenue up to Rp10 trillion in the pandemic-stricken year of 2020. This is a 6.4 percent growth compared to its 2019 revenue of Rp9.4 trillion.
Their 2020 earnings were mostly boosted by the distribution segment that significantly grew 26.81 percent or Rp814.68 billion from the previous year’s Rp3.03 trillion.
Other segments that contributed to Kimia Farma growth were health clinic services and clinical laboratories that surged 316.71 percent from Rp182.04 billion in 2019 to 758.58 billion in 2020. The company’s operating profit also grew 30.17 percent to Rp653.02 billion compared to 2019.
Despite an optimistic projection for 2021, Kimia Farma believes that the ongoing Covid-19 pandemic will be a constant challenge for this year.
Read: Kimia Farma Responds to Alleged Use of Secondhand Rapid Test Kits in Medan
BISNIS.COM